Neurocrine Biosciences Q3 2025 Financial Results

Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported total net product sales of $790 million, representing a 28% year-over-year growth. INGREZZA, a key product, achieved net product sales of $687 million, reflecting a 12% year-over-year growth. CRENESSITY, another significant product, reported net product sales of $98 million with 540 total new patient enrollment start forms. The company also highlighted recent clinical and corporate developments, including the initiation of a second Phase 3 registrational clinical trial for direclidine, a potential treatment for schizophrenia. Neurocrine Biosciences reaffirmed its full-year 2025 INGREZZA guidance and updated its financial outlook. The company continues to focus on advancing transformative therapies in neuroscience.